APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Melanocortin Receptor 4

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Melanocortin Receptor 4 Market Outlook and Growth Opportunities 2026

Report ID 174011690419 December 2025193 pages

Choose your research edition.

Industry ResearchMelanocortin Receptor 4 Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Melanocortin Receptor 4 Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Melanocortin Receptor 4 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Melanocortin Receptor 4 Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Melanocortin Receptor 4 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Melanocortin Receptor 4 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Melanocortin Receptor 4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Melanocortin Receptor 4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Melanocortin Receptor 4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Melanocortin Receptor 4 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Melanocortin Receptor 4 market include Pfizer Inc., AstraZeneca Plc, Rhythm Pharmaceuticals, Inc., Retrophin Inc., Palatin Technologies, Inc., Obexia AG and Mallinckrodt Plc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Melanocortin Receptor 4 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Melanocortin Receptor 4 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Melanocortin Receptor 4 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Melanocortin Receptor 4 market.

Melanocortin Receptor 4 Segment by Company

Pfizer Inc.

AstraZeneca Plc

Rhythm Pharmaceuticals, Inc.

Retrophin Inc.

Palatin Technologies, Inc.

Obexia AG

Mallinckrodt Plc

Melanocortin Receptor 4 Segment by Type

Cosyntropin

Corticotropin

Bremelanotide

Others

Melanocortin Receptor 4 Segment by Application

Genito Urinary System

Infection Disease

Women's Health

Metabolic Disorder

Others

Melanocortin Receptor 4 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Melanocortin Receptor 4 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Melanocortin Receptor 4 key companies, revenue, market share, and recent developments.

3. To split the Melanocortin Receptor 4 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Melanocortin Receptor 4 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Melanocortin Receptor 4 significant trends, drivers, influence factors in global and regions.

6. To analyze Melanocortin Receptor 4 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Melanocortin Receptor 4 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Melanocortin Receptor 4 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Melanocortin Receptor 4.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Melanocortin Receptor 4 industry.

Chapter 3: Detailed analysis of Melanocortin Receptor 4 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Melanocortin Receptor 4 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Melanocortin Receptor 4 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Melanocortin Receptor 4 Industry Trends Table 2. Melanocortin Receptor 4 Industry Drivers Table 3. Melanocortin Receptor 4 Industry Opportunities and Challenges Table 4. Melanocortin Receptor 4 Industry Restraints Table 5. Global Melanocortin Receptor 4 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Melanocortin Receptor 4 Revenue Share by Company (2021-2026) Table 7. Global Melanocortin Receptor 4 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Melanocortin Receptor 4 Key Company Manufacturing Base & Headquarters Table 9. Global Melanocortin Receptor 4 Company, Product Type & Application Table 10. Global Melanocortin Receptor 4 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Melanocortin Receptor 4 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cosyntropin Table 15. Significant Companies of Corticotropin Table 16. Significant Companies of Bremelanotide Table 17. Significant Companies of Others Table 18. Global Melanocortin Receptor 4 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Melanocortin Receptor 4 Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Melanocortin Receptor 4 Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Melanocortin Receptor 4 Sales Value Share by Type (2021-2026) Table 22. Global Melanocortin Receptor 4 Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Genito Urinary System Table 24. Significant Companies of Infection Disease Table 25. Significant Companies of Women's Health Table 26. Significant Companies of Metabolic Disorder Table 27. Significant Companies of Others Table 28. Global Melanocortin Receptor 4 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Melanocortin Receptor 4 Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Melanocortin Receptor 4 Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Melanocortin Receptor 4 Sales Value Share by Application (2021-2026) Table 32. Global Melanocortin Receptor 4 Sales Value Share by Application (2027-2032) Table 33. Global Melanocortin Receptor 4 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Melanocortin Receptor 4 Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Melanocortin Receptor 4 Sales Value Share by Region (2021-2026) Table 36. Global Melanocortin Receptor 4 Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Melanocortin Receptor 4 Sales Value Share by Region (2027-2032) Table 38. Global Melanocortin Receptor 4 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Melanocortin Receptor 4 Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Melanocortin Receptor 4 Sales Value Market Share by Country (2021-2026) Table 41. Global Melanocortin Receptor 4 Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Melanocortin Receptor 4 Sales Value Market Share by Country (2027-2032) Table 43. Pfizer Inc. Company Information Table 44. Pfizer Inc. Business Overview Table 45. Pfizer Inc. Melanocortin Receptor 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Pfizer Inc. Melanocortin Receptor 4 Product Portfolio Table 47. Pfizer Inc. Recent Development Table 48. AstraZeneca Plc Company Information Table 49. AstraZeneca Plc Business Overview Table 50. AstraZeneca Plc Melanocortin Receptor 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. AstraZeneca Plc Melanocortin Receptor 4 Product Portfolio Table 52. AstraZeneca Plc Recent Development Table 53. Rhythm Pharmaceuticals, Inc. Company Information Table 54. Rhythm Pharmaceuticals, Inc. Business Overview Table 55. Rhythm Pharmaceuticals, Inc. Melanocortin Receptor 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Rhythm Pharmaceuticals, Inc. Melanocortin Receptor 4 Product Portfolio Table 57. Rhythm Pharmaceuticals, Inc. Recent Development Table 58. Retrophin Inc. Company Information Table 59. Retrophin Inc. Business Overview Table 60. Retrophin Inc. Melanocortin Receptor 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Retrophin Inc. Melanocortin Receptor 4 Product Portfolio Table 62. Retrophin Inc. Recent Development Table 63. Palatin Technologies, Inc. Company Information Table 64. Palatin Technologies, Inc. Business Overview Table 65. Palatin Technologies, Inc. Melanocortin Receptor 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Palatin Technologies, Inc. Melanocortin Receptor 4 Product Portfolio Table 67. Palatin Technologies, Inc. Recent Development Table 68. Obexia AG Company Information Table 69. Obexia AG Business Overview Table 70. Obexia AG Melanocortin Receptor 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Obexia AG Melanocortin Receptor 4 Product Portfolio Table 72. Obexia AG Recent Development Table 73. Mallinckrodt Plc Company Information Table 74. Mallinckrodt Plc Business Overview Table 75. Mallinckrodt Plc Melanocortin Receptor 4 Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Mallinckrodt Plc Melanocortin Receptor 4 Product Portfolio Table 77. Mallinckrodt Plc Recent Development Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Melanocortin Receptor 4 Product Image Figure 2. Global Melanocortin Receptor 4 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Melanocortin Receptor 4 Market Size (2021-2032) & (US$ Million) Figure 4. Global Melanocortin Receptor 4 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cosyntropin Image Figure 8. Corticotropin Image Figure 9. Bremelanotide Image Figure 10. Others Image Figure 11. Global Melanocortin Receptor 4 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Melanocortin Receptor 4 Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Melanocortin Receptor 4 Sales Value Share by Type (2021-2032) Figure 14. Genito Urinary System Image Figure 15. Infection Disease Image Figure 16. Women's Health Image Figure 17. Metabolic Disorder Image Figure 18. Others Image Figure 19. Global Melanocortin Receptor 4 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Melanocortin Receptor 4 Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Melanocortin Receptor 4 Sales Value Share by Application (2021-2032) Figure 22. Global Melanocortin Receptor 4 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Melanocortin Receptor 4 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Melanocortin Receptor 4 Sales Value (2021-2032) & (US$ Million) Figure 25. North America Melanocortin Receptor 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Melanocortin Receptor 4 Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Melanocortin Receptor 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Melanocortin Receptor 4 Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Melanocortin Receptor 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Melanocortin Receptor 4 Sales Value (2021-2032) & (US$ Million) Figure 31. South America Melanocortin Receptor 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Melanocortin Receptor 4 Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Melanocortin Receptor 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Cosyntropin
  • Corticotropin
  • Bremelanotide
  • Others
Applications
  • Genito Urinary System
  • Infection Disease
  • Women's Health
  • Metabolic Disorder
  • Others
Companies covered
  • Pfizer Inc.
  • AstraZeneca Plc
  • Rhythm Pharmaceuticals, Inc.
  • Retrophin Inc.
  • Palatin Technologies, Inc.
  • Obexia AG
  • Mallinckrodt Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Melanocortin Receptor 4 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Melanocortin Receptor 4 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Melanocortin Receptor 4 Market Dynamics
  1. 2.1 Melanocortin Receptor 4 Industry Trends
  2. 2.2 Melanocortin Receptor 4 Industry Drivers
  3. 2.3 Melanocortin Receptor 4 Industry Opportunities and Challenges
  4. 2.4 Melanocortin Receptor 4 Industry Restraints
3 Melanocortin Receptor 4 Market by Company
  1. 3.1 Global Melanocortin Receptor 4 Company Revenue Ranking in 2025
  2. 3.2 Global Melanocortin Receptor 4 Revenue by Company (2021-2026)
  3. 3.3 Global Melanocortin Receptor 4 Company Ranking (2024-2026)
  4. 3.4 Global Melanocortin Receptor 4 Company Manufacturing Base and Headquarters
  5. 3.5 Global Melanocortin Receptor 4 Company Product Type and Application
  6. 3.6 Global Melanocortin Receptor 4 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Melanocortin Receptor 4 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Melanocortin Receptor 4 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Melanocortin Receptor 4 Market by Type
  1. 4.1 Melanocortin Receptor 4 Type Introduction
  2. 4.1.1 Cosyntropin
  3. 4.1.2 Corticotropin
  4. 4.1.3 Bremelanotide
  5. 4.1.4 Others
  6. 4.2 Global Melanocortin Receptor 4 Sales Value by Type
  7. 4.2.1 Global Melanocortin Receptor 4 Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Melanocortin Receptor 4 Sales Value by Type (2021-2032)
  9. 4.2.3 Global Melanocortin Receptor 4 Sales Value Share by Type (2021-2032)
5 Melanocortin Receptor 4 Market by Application
  1. 5.1 Melanocortin Receptor 4 Application Introduction
  2. 5.1.1 Genito Urinary System
  3. 5.1.2 Infection Disease
  4. 5.1.3 Women's Health
  5. 5.1.4 Metabolic Disorder
  6. 5.1.5 Others
  7. 5.2 Global Melanocortin Receptor 4 Sales Value by Application
  8. 5.2.1 Global Melanocortin Receptor 4 Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Melanocortin Receptor 4 Sales Value by Application (2021-2032)
  10. 5.2.3 Global Melanocortin Receptor 4 Sales Value Share by Application (2021-2032)
6 Melanocortin Receptor 4 Regional Value Analysis
  1. 6.1 Global Melanocortin Receptor 4 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Melanocortin Receptor 4 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Melanocortin Receptor 4 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Melanocortin Receptor 4 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Melanocortin Receptor 4 Sales Value (2021-2032)
  7. 6.3.2 North America Melanocortin Receptor 4 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Melanocortin Receptor 4 Sales Value (2021-2032)
  10. 6.4.2 Europe Melanocortin Receptor 4 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Melanocortin Receptor 4 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Melanocortin Receptor 4 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Melanocortin Receptor 4 Sales Value (2021-2032)
  16. 6.6.2 South America Melanocortin Receptor 4 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Melanocortin Receptor 4 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Melanocortin Receptor 4 Sales Value Share by Country, 2025 VS 2032
7 Melanocortin Receptor 4 Country-level Value Analysis
  1. 7.1 Global Melanocortin Receptor 4 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Melanocortin Receptor 4 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Melanocortin Receptor 4 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Melanocortin Receptor 4 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Melanocortin Receptor 4 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Melanocortin Receptor 4 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Melanocortin Receptor 4 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer Inc.
  2. 8.1.1 Pfizer Inc. Company Information
  3. 8.1.2 Pfizer Inc. Business Overview
  4. 8.1.3 Pfizer Inc. Melanocortin Receptor 4 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Inc. Melanocortin Receptor 4 Product Portfolio
  6. 8.1.5 Pfizer Inc. Recent Developments
  7. 8.2 AstraZeneca Plc
  8. 8.2.1 AstraZeneca Plc Company Information
  9. 8.2.2 AstraZeneca Plc Business Overview
  10. 8.2.3 AstraZeneca Plc Melanocortin Receptor 4 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Plc Melanocortin Receptor 4 Product Portfolio
  12. 8.2.5 AstraZeneca Plc Recent Developments
  13. 8.3 Rhythm Pharmaceuticals, Inc.
  14. 8.3.1 Rhythm Pharmaceuticals, Inc. Company Information
  15. 8.3.2 Rhythm Pharmaceuticals, Inc. Business Overview
  16. 8.3.3 Rhythm Pharmaceuticals, Inc. Melanocortin Receptor 4 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Rhythm Pharmaceuticals, Inc. Melanocortin Receptor 4 Product Portfolio
  18. 8.3.5 Rhythm Pharmaceuticals, Inc. Recent Developments
  19. 8.4 Retrophin Inc.
  20. 8.4.1 Retrophin Inc. Company Information
  21. 8.4.2 Retrophin Inc. Business Overview
  22. 8.4.3 Retrophin Inc. Melanocortin Receptor 4 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Retrophin Inc. Melanocortin Receptor 4 Product Portfolio
  24. 8.4.5 Retrophin Inc. Recent Developments
  25. 8.5 Palatin Technologies, Inc.
  26. 8.5.1 Palatin Technologies, Inc. Company Information
  27. 8.5.2 Palatin Technologies, Inc. Business Overview
  28. 8.5.3 Palatin Technologies, Inc. Melanocortin Receptor 4 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Palatin Technologies, Inc. Melanocortin Receptor 4 Product Portfolio
  30. 8.5.5 Palatin Technologies, Inc. Recent Developments
  31. 8.6 Obexia AG
  32. 8.6.1 Obexia AG Company Information
  33. 8.6.2 Obexia AG Business Overview
  34. 8.6.3 Obexia AG Melanocortin Receptor 4 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Obexia AG Melanocortin Receptor 4 Product Portfolio
  36. 8.6.5 Obexia AG Recent Developments
  37. 8.7 Mallinckrodt Plc
  38. 8.7.1 Mallinckrodt Plc Company Information
  39. 8.7.2 Mallinckrodt Plc Business Overview
  40. 8.7.3 Mallinckrodt Plc Melanocortin Receptor 4 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mallinckrodt Plc Melanocortin Receptor 4 Product Portfolio
  42. 8.7.5 Mallinckrodt Plc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst